NVS Novartis AG

LONDON--Oxford Biomedica PLC (OXB.LN) said Friday that it has signed a new manufacturing and licensing agreement with Novartis (NOVN.VX) worth $14 million.

The consideration includes a $4.3 million equity subscription by Novartis in the company for a global development and commercialization license in oncology under Oxford Biomedica's LentiVector platform. Oxford Biomedica will manufacture lentiviral vectors expressing CTL019/CART-019.

Novartis has also has also been granted license of all Chimeric Antigen Receptor T cell products arising from the collaboration. Under the terms of the three-year deal, Oxford Biomedica is eligible to receive up to $90 million.

Shares of Oxford Biomedica at 0735 GMT trading 14% higher at 4 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires